| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.40K | 17.40K | 199.23K | -8.34M | 6.10M | 2.14M |
| Gross Profit | 29.40K | 17.40K | 199.23K | 66.01K | 63.78K | 151.16K |
| EBITDA | -1.13M | -1.18M | -12.67M | -10.25M | 0.00 | 0.00 |
| Net Income | -2.07M | -3.77M | -12.61M | -10.45M | 4.58M | 803.89K |
Balance Sheet | ||||||
| Total Assets | 10.94M | 11.31M | 13.15M | 25.18M | 32.76M | 24.30M |
| Cash, Cash Equivalents and Short-Term Investments | 74.00K | 382.21K | 297.56K | 931.76K | 1.96M | 2.13M |
| Total Debt | 170.00K | 161.11K | 418.20K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 655.00K | 597.62K | 848.44K | 325.00K | 342.06K | 295.60K |
| Stockholders Equity | 10.29M | 10.71M | 12.30M | 24.85M | 32.42M | 24.00M |
Cash Flow | ||||||
| Free Cash Flow | -1.16M | -1.57M | -1.22M | -2.20M | -1.48M | -1.19M |
| Operating Cash Flow | -1.16M | -1.57M | -1.22M | -2.20M | -1.48M | -1.19M |
| Investing Cash Flow | -442.39K | -406.39K | 151.92K | -1.63M | -2.50M | -1.86M |
| Financing Cash Flow | 1.55M | 1.65M | 431.54K | 2.80M | 3.81M | 4.17M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | £202.88M | 48.57 | 9.59% | 0.80% | 22.80% | -32.13% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
60 Neutral | £36.24M | 207.58 | ― | ― | 1.73% | -68.87% | |
58 Neutral | £6.08M | ― | ― | ― | ― | ― | |
51 Neutral | £2.50M | 93.33 | 0.89% | ― | ― | ― | |
40 Underperform | £3.46M | -1.29 | -19.70% | ― | -77.04% | 86.67% | |
40 Underperform | £2.15M | -0.61 | -213.44% | ― | 5.29% | 72.50% |
Tern plc has lost its entire limited partner interest in the Sure Valley Ventures Enterprise Capital Fund LP (SVV2) after being classified as a defaulting investor under the fund’s limited partnership agreement, following its request for relief from funding obligations in late 2025. The company has been informed it will receive effectively no consideration for its former SVV2 interest and faces claims from the fund’s general partner for approximately £40,000 in default interest and costs, plus a further deemed indemnity exposure of about £184,000 through 2032; Tern is seeking legal advice, and the outcome could affect its financial obligations and underscores the risks around its fund-based investment strategy.
The most recent analyst rating on (GB:TERN) stock is a Hold with a £0.58 price target. To see the full list of analyst forecasts on Tern plc stock, see the GB:TERN Stock Forecast page.
Tern Plc has announced that investor presentation materials from its recent online event featuring portfolio companies Device Authority and Talking Medicines are now available to view via published links, with a recording of the session to be hosted shortly on the company’s website. By making these detailed presentations and the event recording accessible, Tern is enhancing transparency and engagement with investors, offering deeper insight into the progress and prospects of its key IoT-focused holdings, which may help support stakeholder understanding of the portfolio’s development and strategic positioning.
The most recent analyst rating on (GB:TERN) stock is a Hold with a £0.68 price target. To see the full list of analyst forecasts on Tern plc stock, see the GB:TERN Stock Forecast page.
Tern Plc has scheduled an online investor presentation and Q&A session for 5.30 p.m. GMT on Wednesday 7 January 2026, to be led by members of its management team alongside executives from portfolio companies Device Authority and Talking Medicines. The event, open to both existing and prospective shareholders, is designed to provide direct engagement with management and greater visibility into Tern’s portfolio, underlining the company’s efforts to enhance investor communication and transparency around its strategy and the progress of its IoT investments.
The most recent analyst rating on (GB:TERN) stock is a Hold with a £0.63 price target. To see the full list of analyst forecasts on Tern plc stock, see the GB:TERN Stock Forecast page.
Tern Plc has been issued approximately £230,000 in new unsecured convertible loan notes by Talking Medicines Limited, in exchange for canceling existing short-term loans totaling about £180,000. This move increases Tern’s total convertible loan note holding in Talking Medicines to approximately £0.52 million while maintaining its 23.8% equity stake. Talking Medicines is raising up to £1.0 million through similar convertible loan notes to enhance its capabilities in the healthcare advertising market, which it aims to revolutionize with advanced data science and AI.
The most recent analyst rating on (GB:TERN) stock is a Hold with a £0.63 price target. To see the full list of analyst forecasts on Tern plc stock, see the GB:TERN Stock Forecast page.
Tern Plc has announced an update regarding its capital commitment to Sure Valley Ventures Enterprise Capital Fund LP (SVV2). The company has invested approximately £1.3 million into SVV2 but faces challenges in meeting further capital calls due to insufficient funds and limited access to future funding. As a result, Tern has requested relief from its funding obligations, leading to its classification as a ‘defaulting investor’ under the SVV2 Limited Partnership Agreement. This status may affect Tern’s rights to distributions and recovery compared to non-defaulting investors. Despite these challenges, Tern aims to maintain its focus on protecting shareholder interests and long-term value creation from its key portfolio companies.
The most recent analyst rating on (GB:TERN) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Tern plc stock, see the GB:TERN Stock Forecast page.
Tern Plc has announced the extension of the maturity dates for approximately £0.3 million of convertible loan notes in Talking Medicines Limited to 21 November 2029. This strategic move is expected to enhance Tern’s negotiating position for a potential exit from its investment in Talking Medicines, aligning the terms of the loan notes with previous agreements.
The most recent analyst rating on (GB:TERN) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Tern plc stock, see the GB:TERN Stock Forecast page.
Tern plc announced that its total issued ordinary share capital consists of 672,713,705 Ordinary Shares, each with one voting right, and none held in Treasury. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:TERN) stock is a Sell with a £0.50 price target. To see the full list of analyst forecasts on Tern plc stock, see the GB:TERN Stock Forecast page.